文献速递免疫规划传染病防控与疫情报告

2015/16季度流感疫苗对欧洲老年人甲型H1N1pdm09和乙型流感住院的保护效果:I-MOVE+项目结果

2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project.
PubMed 文献 · Euro Surveill · 2017-01-01

在11个欧洲国家27家医院开展多中心检测阴性病例对照研究,评估2015/16季度疫苗对≥65岁人群甲型H1N1pdm09和乙型流感住院的保护效果。纳入甲型H1N1pdm09病例355例、乙型病例110例、对照1274例。调整后疫苗效果:甲型H1N1pdm09为42%(95%CI:22-57),乙型为52%(95%CI:24-70),在糖尿病、癌症、肺病和心脏病患者中亦观察到中等保护。

要点

  • 2015/16季度疫苗对老年人甲型H1N1pdm09住院的调整后疫苗效果为42%(95%CI:22-57)。
  • 对乙型流感住院的调整后疫苗效果为52%(95%CI:24-70)。
  • 在糖尿病、癌症、肺病和心脏病患者中亦观察到中等疫苗保护。

核心结论

  • 2015/16季度流感疫苗对欧洲老年人甲型H1N1pdm09和乙型流感住院的保护效果为中等,包括糖尿病、癌症、肺病和心脏病患者。

研究设计与样本

  • 多中心检测阴性病例对照研究,在11个欧洲国家的27家医院开展。
  • 研究对象为年龄≥65岁、在症状出现后7天内采样且符合严重急性呼吸道感染定义的患者。
  • 纳入甲型H1N1pdm09病例355例、乙型流感病例110例、对照1274例。
  • 使用逻辑回归估计疫苗效果,并调整潜在混杂因素。

主要发现

  • 针对甲型H1N1pdm09的调整后疫苗效果为42%(95%CI:22-57)。
  • 糖尿病患者中针对甲型H1N1pdm09的调整后疫苗效果为59%(95%CI:23-78),癌症患者为48%(95%CI:5-71),肺病患者为43%(95%CI:8-65),心脏病患者为39%(95%CI:7-60)。
  • 针对乙型流感的调整后疫苗效果为52%(95%CI:24-70)。
  • 糖尿病患者中针对乙型流感的调整后疫苗效果为62%(95%CI:5-85),肺病患者为60%(95%CI:18-80),心脏病患者为36%(95%CI:-23-67)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We conducted a multicentre test-negative case-control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Rondy M, Larrauri A, Casado I, et al. 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project. Euro Surveill. 2017. PMID: 28797322. doi:10.2807/1560-7917.ES.2017.22.30.30580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。